Urologic Health Raises $11 Mn to Advance Non-Invasive Bladder Monitoring System

The financing round was led by an undisclosed strategic investor and included participation from Edge Medical Ventures, SHD Partners, and Longevity Venture Partners.

Urologic Health Inc. has raised $11 million in seed funding to support clinical validation and regulatory clearance efforts for its non-invasive bladder monitoring platform, the niu™ System.

The financing round was led by an undisclosed strategic investor and included participation from Edge Medical Ventures, SHD Partners, and Longevity Venture Partners.

The company said the funding will support the FDA 510(k) regulatory pathway and preparation for its initial commercial launch in the United States. Urologic Health also plans to establish its headquarters in Jersey City.

The niu™ System is designed to monitor bladder function without catheterization, aiming to reduce the discomfort associated with traditional urodynamic testing. The platform is being developed for conditions including overactive bladder, urinary retention, and urinary incontinence.

According to the company, early feasibility studies demonstrated the system’s ability to capture clinically meaningful bladder activity through non-invasive monitoring.

Current urodynamic assessments typically require catheter-based procedures, which can be invasive and uncomfortable for patients. Urologic Health said this has created barriers to diagnosis and ongoing monitoring for bladder dysfunction, affecting care access for millions of patients globally.

The company stated that the niu™ System is intended to support longitudinal bladder monitoring, allowing clinicians to track changes in bladder function over time instead of relying on isolated diagnostic procedures.

Urologic Health also said the platform incorporates AI-based analytics to convert bladder activity data into diagnostic insights for clinicians. The company was co-founded by Adam Yaacov and Dr. Noam Omer.

In addition to reducing invasiveness, the company said the system is designed to simplify workflow execution for clinical teams and potentially increase diagnostic throughput.

Urologic Health was founded and incubated through the MEDX Xelerator venture studio, now operating as EdgeLabs. The company said its operating model combines engineering operations in Israel with commercial and operational support in the United States to accelerate clinical and regulatory development.

Shai Policker, managing partner at Edge Medical Ventures and chairman of Urologic Health’s board, said the venture studio structure is intended to help medical device companies move more quickly through clinical validation and regulatory processes.

Stay tuned for more such updates on Digital Health News